CommercialPrior AuthMedium impact
Elosulfase Alfa (Vimizim®)
BCBS Tennessee·TN · Genetics, Pediatrics, Internal Medicine·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
BlueCross BlueShield of Tennessee is establishing a new medical policy for Elosulfase Alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA, Morquio A syndrome), effective October 31, 2026. The policy requires prior authorization, specific diagnostic confirmation via enzyme assay or genetic testing, clinical documentation of disease symptoms, and prescriber specialization in metabolic or lysosomal storage disorders. Authorization is granted for 12 months with continuation based on documented clinical response.
Action Required
Before October 31, 2026: (1) Billing team must implement prior authorization requirement in the billing system for Elosulfase Alfa (Vimizim®) claims on BlueCross BlueShield of Tennessee plans. (2) Configure system to require initial submission of: enzyme assay or genetic testing documentation confirming N-acetylgalactosamine 6-sulfatase deficiency AND baseline clinical documentation of MPS IVA symptoms. (3) For continuation/reauthorization requests: configure system to require chart notes documenting clinically positive response (improvement, stabilization, or slowing of disease progression). (4) Update prior auth forms and clinical intake templates to verify prescriber specializes in metabolic disease or lysosomal storage disorders. (5) Train billing and clinical staff on the 12-month authorization cycle and continuation requirements. (6) Add coding guidance for Vimizim dosing verification (2mg/kg IV weekly) during claim adjudication. Claims submitted without proper prior authorization or required documentation will be denied.